Dimers Aren't Forever: CD80 Breaks up with PD-L1.
Immunity
; 51(6): 972-974, 2019 12 17.
Article
em En
| MEDLINE
| ID: mdl-31951541
ABSTRACT
Targeting the CTLA-4 and PD-1 "checkpoints" is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antígenos CD28
/
Antígeno B7-H1
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article